TY - JOUR
T1 - Physical Health and Mental Fatigue Disability Associated with Long COVID
T2 - Baseline Results from a US Nationwide Cohort
AU - Lau, Bryan
AU - Wentz, Eryka
AU - Ni, Zhanmo
AU - Yenokyan, Karine
AU - Vergara, Candelaria
AU - Mehta, Shruti H.
AU - Duggal, Priya
N1 - Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2025/2
Y1 - 2025/2
N2 - Background: Persistent symptoms after severe acute respiratory disease coronavirus 2 (SARS-COV-2; long COVID) occur in 10%-55% of individuals, but the impact on daily functioning and disability remains unquantified. Methods: To characterize disability associated with long COVID, we analyzed baseline data from an online, US-based cohort study. Adult participants included those reporting a history of COVID-19 (n = 8874) or never having COVID-19 (n = 633) without prior disability. The main outcomes were self-reported physical mobility, instrumental activities of daily living (IADL), and mental fatigue disability, assessed by measuring 5 disability components: difficulty walking a quarter mile or climbing 10 stairs (mobility), difficulty doing light or heavy housework (IADL), and Wood Mental Fatigue Inventory score (mental fatigue). Results: Of 7926 participants with long COVID, 65% were classified with at least one disability, as compared with 6% and 14% for resolved COVID and no COVID, respectively. Additionally, 22% were classified as disabled in all 3 categories. Age, prior comorbidity, increased body mass index, female sex, COVID-19 hospitalization, non-white/multi-race were associated with higher disability burden. Dizziness and heavy limbs at infection were associated with disability regardless of hospitalization. Dyspnea and tremors were associated with disability in non-hospitalized individuals. Vaccination was protective against disability. Conclusions: We observed a high burden of new disability associated with long COVID, which has serious implications for individual and societal health. Longitudinal evaluation of COVID-19 patients is necessary to identify patterns of recovery and treatment options.
AB - Background: Persistent symptoms after severe acute respiratory disease coronavirus 2 (SARS-COV-2; long COVID) occur in 10%-55% of individuals, but the impact on daily functioning and disability remains unquantified. Methods: To characterize disability associated with long COVID, we analyzed baseline data from an online, US-based cohort study. Adult participants included those reporting a history of COVID-19 (n = 8874) or never having COVID-19 (n = 633) without prior disability. The main outcomes were self-reported physical mobility, instrumental activities of daily living (IADL), and mental fatigue disability, assessed by measuring 5 disability components: difficulty walking a quarter mile or climbing 10 stairs (mobility), difficulty doing light or heavy housework (IADL), and Wood Mental Fatigue Inventory score (mental fatigue). Results: Of 7926 participants with long COVID, 65% were classified with at least one disability, as compared with 6% and 14% for resolved COVID and no COVID, respectively. Additionally, 22% were classified as disabled in all 3 categories. Age, prior comorbidity, increased body mass index, female sex, COVID-19 hospitalization, non-white/multi-race were associated with higher disability burden. Dizziness and heavy limbs at infection were associated with disability regardless of hospitalization. Dyspnea and tremors were associated with disability in non-hospitalized individuals. Vaccination was protective against disability. Conclusions: We observed a high burden of new disability associated with long COVID, which has serious implications for individual and societal health. Longitudinal evaluation of COVID-19 patients is necessary to identify patterns of recovery and treatment options.
KW - Long COVID
KW - Mental fatigue
KW - Physical disability
UR - http://www.scopus.com/inward/record.url?scp=85175205981&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85175205981&partnerID=8YFLogxK
U2 - 10.1016/j.amjmed.2023.08.009
DO - 10.1016/j.amjmed.2023.08.009
M3 - Article
C2 - 37690503
AN - SCOPUS:85175205981
SN - 0002-9343
VL - 138
SP - 287-297.e21
JO - American Journal of Medicine
JF - American Journal of Medicine
IS - 2
ER -